<DOC>
	<DOCNO>NCT02789917</DOCNO>
	<brief_summary>It hypothesise dual therapy strategy oral anticoagulation new Factor-Xa-inhibitor apixaban plus clopidogrel superior triple therapy regimen phenprocoumon plus acetylsalicylic acid ( ASA ) clopidogrel respect avoid bleed event patient atrial fibrillation undergo percutaneous coronary intervention set acute coronary syndrome .</brief_summary>
	<brief_title>APixaban vs. PhenpRocoumon Patients With ACS AF : APPROACH-ACS-AF</brief_title>
	<detailed_description>Patients atrial fibrillation ( AF ) present acute coronary syndrome ( ACS ) undergo PCI require triple therapy combination oral anticoagulation ( OAC ) dual anti-platelet therapy . Current guideline recommend regimen consist aspirin , clopidogrel oral anticoagulant . Although effective prevent recurrent ischemia , triple therapy confers elevate bleed risk , also major impact patient ' prognosis survival . Data one randomize trial suggest omit aspirin patient indication triple therapy may reduce risk bleed without increase rate ischemic event . In addition , recently introduce non-vitamin-K oral anticoagulant ( NOACs ) show less bleeding event compare vitamin-K antagonist AF patient . In trial postulate dual therapy consist factor-Xa inhibitor apixaban clopidogrel associate significant low bleeding rate compare traditional triple therapy aspirin , clopidogrel vitamin K antagonist ( VKA ) . To test hypothesis , patient atrial fibrillation , underwent PCI set ACS randomize either dual therapy ( apixaban+clopidogrel ) triple therapy ( aspirin+clopiodgrel+VKA ) . The patient followed-up 6 month randomization .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>Signed write informed consent Patients ACS successful percutaneous coronary intervention Indication oral anticoagulation due nonvalvular atrial fibrillation atrial flutter ( CHA2DS2VASc score ≥ 2 ) Males Females , age ≥ 18 Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug . Women must breastfeed WOCBP must agree follow instruction method ( ) contraception duration treatment study drug plus 30 day ( duration ovulatory cycle ) posttreatment completion . However must still undergo pregnancy test . Age &lt; 18 year History intracranial bleeding Active bleed History TIMI major bleed accord TIMI and/or type ≥3b BARC criterion last 6 month History peptic ulcer last 6 month Subjects history complicate prolonged cardiogenic shock last two week prior randomization . A complicated prolonged cardiogenic shock define cardiogenic shock require mechanical ventilation cardiovascular support positive inotropic drug ( i.v . catecholamine ) ≥7 day Planned major surgery study course plan discontinuation antithrombotic therapy Expected life expectancy less year and/or severe illness ( e.g . malignancy ) Mechanical valve replacement Valvular atrial fibrillation Severe renal insufficiency ( creatinine clearance &lt; 30ml/min ) Severe liver insufficiency ( ChildPughclass C ) elevate hepatic transaminase &gt; 2 time upper limit normal Patient 's inability fully comply study protocol Known persistent abuse medication , drug alcohol reliable investigator individual case Subjects known contraindication apixaban , phenprocoumon , clopidogrel ASA treatment , hypersensitive drug substance component product Relevant hematologic deviation : platelet count &lt; 50 G/L platelet count &gt; 600 G/L Current plan pregnancy nursing woman , woman 90 day childbirth . Females childbearing potential , use willing use medically reliable method contraception entire study duration ( oral , injectable , implantable contraceptive , intrauterine contraceptive device ) unless surgically sterilize / hysterectomized criterion consider sufficiently</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ACS</keyword>
	<keyword>Triple-Therapy</keyword>
	<keyword>AF</keyword>
	<keyword>oral anticoagulation ( OAC )</keyword>
	<keyword>non-vitamin-K oral anticoagulant ( NOAC )</keyword>
</DOC>